Inflammatory muscle disease: Clinical presentation and assessment of patients

Current Rheumatology Reports

Volumn 9, Issue 4, 2007, Pages 273-279

  Alexanderson, Helene ^b   Lundberg, Ingrid E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CREATINE KINASE; MUSCLE ENZYME;

CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME BLOOD LEVEL; FOLLOW UP; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMOBILIZATION; INFLAMMATORY DISEASE; LUNG FUNCTION TEST; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; QUALITY OF LIFE; REVIEW; VISUAL ANALOG SCALE;

EID: 34547891054     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0044-8     Document Type: Review

References (50)

1. Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193-208.
2. Dalakas MC: Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991, 325:1487-1498.
3. Plotz PH, Rider LG, Targoff IN, et al.: NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995, 122:715-724.
4. Miller FW, Rider LG, Chung YL, et al.: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001, 40:1262-1273.
5. World Health Organization: The international classification of functioning, disability and health. Geneva: World Health Organization; 2001.
6. IMACS website. https://dir-apps.niehs.nih.gov/imacs/. Accessed June 7, 2007.
7. Alexanderson H, Broman L, Tollback A, et al.: Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2006, 55:114-122. In this paper, a new myositis-specific outcome measure of impairment, functional-index 2, was validated. This test of muscle endurance measures number of repetitions performed in proximal and distal muscle groups. This is a valuable tool to be used, preferably by physical therapists, in clinical practice and research.
8. Alexanderson H, Dastmalchi M, Lundberg IE: Patients with chronic inflammatory myopathies have reduced muscle endurance rather than reduced muscle strength. Arthritis Rheum 2006, 54(Suppl):S658.
9. Gerami P, Schope JM, McDonald L, et al.: A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006, 54:597-613. Through a comprehensive review of literature, many adult dermatomyositis cases were collected, enabling the identification of the cause and frequency of extraskin and extramuscular manifestation. The authors proposed a new subgroup of myositis to be included in classification of idiopathic inflammatory myopathies, and they suggested definition of this subgroup, CADM.
10. Suda T, Fujisawa T, Enomoto N, et al.: Interstitial lung disease associated with amyopathic dermatomyositis. Eur Respir J 2006, 28:1005-1012.
11. Fathi M, Dastmalchi M, Rasmussen E, et al.: Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004, 63:297-301. This study suggests that ILD may be more frequent in patients with polymyositis or dermatomyositis at time of diagnosis than had been thought previously, when sensitive tests such as HRCT and pulmonary function tests were used. As this may affect treatment decisions, careful investigation for ILD at time of diagnosis is suggested.
12. Lundberg IE: The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 2006, 45(Suppl 4):iv18-iv21.
13. Finsterer J, Stollberger C, Avanzini M, et al.: Restrictive cardiomyopathy in dermatomyositis. Scand J Rheumatol 2006, 35:229-232.
14. Ohata S, Shimada T, Shimizu H, et al.: Myocarditis associated with polymyositis diagnosed by gadolinium-DTPA enhanced magnetic resonance imaging. J Rheumatol 2002, 29:861-862.
15. Allanore Y, Vignaux O, Arnaud L, et al.: Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann Rheum Dis 2006, 65:249-252. This study suggests that MRI of the heart could be a useful tool to assess effects of immunosuppressive treatment on myocarditis in patients with myositis.
16. Brouwer R, Hengstman GJ, Vree Egberts W, et al.: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116-123.
17. Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
18. Sato S, Kuwana M, Hirakata M: Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford) 2007, 46:842-845. This small case series, one of the largest of patients with the unusual antisynthetase autoantibody anti-OJ, suggest that anti-OJ is strongly associated with ILD.
19. Hengstman GJ, Vree Egberts WT, Seelig HP, et al.: Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen. Ann Rheum Dis 2006, 65:242-245. In this European multicenter study, no clinical characteristics were found to correlate to autoantibodies directed to different fragments of the Mi-2β antigen, which is in contrast to previous studies where mostly antibody reactivity to the NM epitope, thought to be the major epitope of the Mi-2 antigen, were used.
20. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al.: Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006, 65:1635-1638. In a retrospective multicenter study including 23 patients with anti-SRP autoantibodies, a characteristic histopathologic phenotype was identified with frequent necrotic muscle fibers but with sparse inflammatory infiltrates, named necrotizing myopathy. The patients had a reasonably favorable response to immunosuppressive therapy and good prognosis.
21. Targoff IN, Mamyrova G, Trieu EP, et al.: A novel autoantibody to 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689. In this carefully performed study, a novel autoantibody was found with a remarkable specificity for patients with dermatomyositis, both in children and adults. Interestingly, it was associated with malignancies in dermatomyositis patients. This autoantibody has a large potential as a biomarker of the subset of dermatomyositis with cancer, but this needs to be tested in an independent cohort.
22. Cherin P, Pelletier S, Teixiera A, et al.: Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002, 46:467-474.
23. Danieli MG, Malcangi G, Palmieri C, et al.: Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002, 61:37-41.
24. Hengstman GJ, van den Hoogen FH, Barrera P, et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor- alpha: preliminary results. Eur Neurol 2003, 50:10-15.
25. Wiesinger GF, Quittan M, Aringer M, et al.: Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998, 37:196-200.
26. Wiesinger GF, Quittan M, Graninger, et al.: Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 1998, 37:1338-1342.
27. Varju C, Petho E, Kutas R, et al.: The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehahil 2003, 17:83-87.
28. Spector SA, Lemmer JT, Koffman BM, et al.: Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997, 20:1242-1248.
29. Badrising UA, Maat-Schieman ML, Ferrari MD, et al.: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002, 51:369-372.
30. Arnardottir S, Alexanderson H, Lundberg IE, et al.: Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehahil Med 2003, 35:31-35.
31. Josefson A, Romanus E, Carlsson J: A functional index in myositis. J Rheumatol 1996, 23:1380-1384.
32. Alexanderson H, Stenstrom CH, Lundberg I: The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000, 29:295-301.
33. Vencovsky J, Jarosova K, Machacek S, et al.: Cyclosporine A versus methotrexate in treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000, 29:95-102.
34. Heikkila S, Viitanen JV, Kautiainen H, et al.: Rehabilitation in myositis. Physiotherapy 2001, 87:301-309.
35. Newcomer KL, Krug HE, Mahowald ML: Validity and reliability of the timed-stands test for patients with rheumatoid arthritis and other rheumatic diseases. J Rheumatol 1993, 20:21-27.
36. Agarwal S, Kiely PD: Two simple, reliable and valid tests of proximal muscle function, and their application to the management of idiopathic inflammatory myositis. Rheumatol 2006, 45:874-879. A simple, easy-to-perform test in clinical practice, but it must be validated and tested for sensitivity to change in myositis patients.
37. Rider LG, Feldman BM, Perez MD, et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997, 40:1976-1983.
38. Rider LG: Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin N Am 2002, 28:935-977.
39. Huber AM, Hicks JE, Lachenbruch PA, et al.: Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001, 28:1106-1111.
40. Isenberg DA, Allen E, Farewell V, et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004, 43:49-54.
41. Park JH, Vital TL, Ryder NM, et al.: Magnetic resonance imaging and p-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994, 37:736-746.
42. Weber MA, Weber MA, Jappe U, et al.: Contrast-enhanced ultrasound in dermatomyositis and polymyositis. J Neurol 2006, 253:1625- 1632. Contrast-enhanced ultrasound is an interesting noninvasive technique to detect inflammation in muscles, which has potential use as an outcome measure and to identify sites for muscle biopsy. However, it must be further validated in longitudinal studies and compared with muscle biopsies.
43. Weber MA, Krix M, Jappe U, et al.: Pathologic skeletal muscle perfusion in patients with myositis: detection with quantitative contrast-enhanced US - initial results. Radiology 2006, 238:640-649.
44. Fries JF, Spitz P, Kraines RG, et al.: Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145.
45. Alexanderson H, Lundberg IE, Stenstrom CH: Development of the myositis activities profile - validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol 2002, 29:2386-2392.
46. World Health Organization: International classification of impairment, disability and handicap. Beta-2 draft, full version. Geneva: World Health Organization; 1999.
47. Verhoeven AC, Boers M, van der Linden S: Validity of the MACTAR questionnaire as a functional index in a rheumatoid arthritis clinical trial. J Rheumatol 2000, 27:2801-2809.
48. Alemo Munters L, van Vollenhoven R, Alexanderson H: Measurement properties of the Swedish MACTAR. Arthritis Rheum 2006, 54(Suppl):S503.
49. Ware JE, Sherbourne CD: The MOS 36-item short-form health survey: conceptual framework and item selection. Med Care 1992, 30:473-483.
50. Sultan SM, Ioannou Y, Moss K, et al.: Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002, 41:22-26.